A5008087370- Pancreatic and Hepatic Oncology Research
- Bone and Dental Protein Studies
- Cancer Genomics and Diagnostics
- Radiomics and Machine Learning in Medical Imaging
- Cancer Research and Treatments
- Proteoglycans and glycosaminoglycans research
- Connective tissue disorders research
- Mathematical Biology Tumor Growth
- Cancer Cells and Metastasis
- Virus-based gene therapy research
- Phagocytosis and Immune Regulation
- Pancreatitis Pathology and Treatment
- Cancer, Hypoxia, and Metabolism
- Nanoplatforms for cancer theranostics
- 3D Printing in Biomedical Research
- Ferroptosis and cancer prognosis
- MRI in cancer diagnosis
- Cell Image Analysis Techniques
- Caveolin-1 and cellular processes
- Epigenetics and DNA Methylation
- Intracranial Aneurysms: Treatment and Complications
- Renal cell carcinoma treatment
- Cancer-related molecular mechanisms research
- Tumors and Oncological Cases
- Advanced Fluorescence Microscopy Techniques
The University of Texas at San Antonio
2024
The University of Texas MD Anderson Cancer Center
2015-2021
University of Puerto Rico, Medical Sciences Campus
2017-2019
Max Planck Society
2018
Max Planck Institute for Biological Cybernetics
2018
University of Puerto Rico System
2015-2017
Abstract Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a heterogeneous disease with variable presentations and natural histories of disease. We hypothesized that different morphologic characteristics PDAC tumors on diagnostic computed tomography (CT) scans would reflect their underlying biology. Experimental Design: developed quantitative method to categorize the morphology pretherapy CT from multiple datasets patients resectable metastatic correlated these patterns clinical/pathologic...
Abstract Purpose: Translation of the patient-derived xenograft (PDX) model into a method for practical personalized cancer treatment is prevented by intense resources and time necessary to generate test each tumorgraft. We aimed develop high-throughput ex vivo drug testing approach that can be used design. Experimental Design: developed unique live tissue sensitivity assay (LTSA), in which precision-cut uniform small slices derived from pancreatic ductal adenocarcinoma PDX tumors were...
Pancreatic ductal adenocarcinoma (PDAC) is lethal cancer whose primary tumor characterized by dense composition of cells, stromal and extracellular matrix (ECM) composed largely collagen. Within the PDAC microenvironment, activated pancreatic stellate cells (PSC) are dominant cell type responsible for collagen deposition. Lumican a secreted proteoglycan that regulates fibril assembly. We have previously identified presence lumican in ECM surrounding associated with improved patient outcome...
Auranofin, a Food and Drug Administration-approved anti-rheumatic agent with anticancer properties for lung ovarian cancer, has never been studied pancreatic cancer. We hypothesize that auranofin may prevent ductal adenocarcinoma progression by inhibition of Txnrd1 HIF-1α.In vitro sensitivity human cell lines was determined based on IC50. Western blot assays were used to interrogate mechanisms apoptosis resistance. Ex vivo live tissue slice xenografts allowed testing larger number PDX...
Intra-tumoral expression of the serine hydrolase carboxylesterase 2 (CES2) contributes to activation pro-drug irinotecan in pancreatic ductal adenocarcinoma (PDAC). Given other potential roles CES2, we assessed its regulation, downstream effects, and contribution tumor development PDAC. Association between mRNA CES2 tumors overall survival was using The Cancer Genome Atlas. Cell viability, clonogenic, anchorage-independent growth assays as well an orthotopic mouse model PDAC were used...
Delta-24-RGD (DNX-2401) is a conditional replication-competent oncolytic virus engineered to preferentially replicate in and lyse tumor cells with abnormality of p16/RB/E2F pathway. In phase I clinical trial, has shown favorable safety profile promising efficacy brain tumor, which prompted us evaluate its anticancer activity pancreatic ductal adenocarcinoma (PDAC), also high frequency homozygous deletion promoter methylation CDKN2A encoding the p16 protein. Our results demonstrate that can...
PURPOSE The combination chemotherapy of fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) has provided clinically meaningful improvement for pancreatic ductal adenocarcinoma (PDAC). We previously uncovered a role the serine hydrolase carboxylesterase 2 (CES2) in mediating intratumoral activation prodrug constituent FOLFIRINOX. aimed to further test predictive value CES2 response irinotecan using patient-derived xenograft (PDX) models elucidate determinants expression...
235 Background: Heterotopic patient-derived xenografts (PDX) have been used to assess response therapy however they underrepresent the role of tumor microenvironment and rarely develop metastasis, both which are overcome by orthotopic models. Fluorescent mouse models require invasive measures determine bioluminescence. Ultrasonography (US) is a cost-effective, non-invasive imaging technique that has in genetically engineered pancreatic cancer for three-dimensional (3D) acquisition volume,...
236 Background: Auranofin, an FDA anti-rheumatic agent shown to have anticancer properties for lung and ovarian cancer has never been studied pancreatic cancer. We hypothesize that Auranofin may prevent ductal adenocarcinoma (PDAC) progression by induction of apoptosis. Methods: performed in vitro vivo studies using human PDAC cell lines patient-derived xenografts (PDX) assess activity. Sensitivity the compound was determined based on IC 50 s. Western blot assay used interrogate mechanisms...
Although data suggests little hope for survival when patients present with metastatic pancreatic cancer, recent advances in systemic therapy offer the possibility dramatic tumor responses like those observed other disease sites. Here, we case of a 50-year-old woman who presented adenocarcinoma pancreas two liver metastases and CA 19-9 level 1,659 U/mL. The patient received FOLFIRINOX (leucovorin, 5-fluorouracil, irinotecan, oxaliplatin) reduction to 23.9 U/mL, complete regression both...
ABSTRACT A combined biomaterial and cell‐based solution to heal critical size bone defects in the craniomaxillofacial area is a promising alternative therapeutic option improve upon autografting, current gold standard. shape memory polymer (SMP) scaffold, composed of biodegradable poly(ε‐caprolactone) coated with bioactive polydopamine, was evaluated mesenchymal stromal cells (MSCs) derived from adipose (ADSC), marrow (BMSC), or umbilical cord (UCSC) tissue their undifferentiated state...
• Lipoblastoma is a benign neoplasm that originates from immature fat cells. It rarely presents on patients older than 3 years of age. Radical excision the best treatment to avoid recurrence.
<p>HPaSteC and Media: Western blot ELISA assay: Vectra Automated Quantitative Pathology Imaging System (VAQPIS, PerkinElmer): Double Immunofluorescence staining (IF), multispectral analysis: Supplementary figure legends:</p>
<p>Vectra Image analysis workflow, Double IF staining of lumican and collagen I, TGF-β secretion in HPSC.</p>
<p>Lumican secretion associated with cell matrix migration.</p>
<p>PDAC cells matrix adhesions were affect by HPSC supernatant of 24 hour's collection.</p>
<p>Supplemental Materials and Methods: Immunohistochemical staining of cleaved caspase 3, statistical analysis the correlation LTSA values with patients' progression free survival; Supplemental Figure legend</p>
<p>Tissue slices after treatment with Gemcitabine (100 µM) or Irinotecan (30 for 48 hours were fixed and embedded immunohistochemical staining of cleaved-Caspase 3 (40X magnification, Bars = 20 µm).</p>
<p>Lumican expression and secretion in HPaSteC with or without TGF-β exposure at 8 24 hours.</p>
<p>Mathematical model simulation of high delta tumor growth (lambda = 1.5)</p>